



1 the planned procedure. TJ kept the appointment, and on February 2, 2013 received an  
2 injection of Phyll G3 from a registered nurse who was not licensed to practice in the State  
3 of Arizona. Shortly after the procedure, TJ began to feel a burning sensation around her  
4 eyes, and complained of blurred vision, dry eyes and a headache.

5 5. Phyll G3 is not approved by the Food and Drug Administration ("FDA") and  
6 cannot be purchased in the United States. It contains a synthetic polymer that is not  
7 considered absorbable in the body, and therefore is permanent in nature and cannot  
8 effectively be neutralized or removed. Additionally, the product is manufactured in Europe.  
9 The manufacturer's package insert and informational web page use poor English syntax,  
10 misspell common words, and use non-standard terminology.

11 6. During a Formal Interview with the Board on this matter on October 1, 2014,  
12 Respondent testified that she was an independent consultant for the medical spa, did not  
13 supervise the unlicensed registered nurse and did not direct the unlicensed registered  
14 nurse to perform the procedure. When asked to explain her understanding about the  
15 source of the product, Respondent testified that she believed that the physician who  
16 owned the practice had obtained the Phyll G3 from a personal source in Mexico.

17 7. Respondent also further testified that she utilized Phyll G3 on approximately  
18 twenty (20) other patients without complication and believed it to be a safe product. The  
19 Board voted to return the matter for further investigation.

20 8. A Medical Consultant ("MC") reviewed six charts and found that for each  
21 patient treated by Respondent, the informed consent document used for each patient was  
22 inadequate and apparently made from a template for a different filler named Juvederm.  
23 Additionally, the informed consent form does not discuss the ingredients contained in  
24 Phyll G3, and does not discuss what happens to the ingredients in a patient's body over  
25 the long term, or whether the product is considered permanent.



1 **ORDER**

2 IT IS HEREBY ORDERED THAT:

3 1. Respondent is issued a Letter of Reprimand.

4 2. Respondent is placed on Probation for a period of six months with the  
5 following terms and conditions:

6 a. **Continuing Medical Education**

7 Respondent shall within 6 months of the effective date of this Order complete a  
8 minimum of 20 hours of Board Staff pre-approved Category I Continuing Medical  
9 Education ("CME") in the areas of legal drug prescribing, ethics, human subjects studies,  
10 and institutional review board investigation of drugs. Respondent shall within **thirty days**  
11 of the effective date of this Order submit her request for CME to the Board for pre-  
12 approval. Upon completion of the CME, Respondent shall provide Board staff with  
13 satisfactory proof of attendance. The CME hours shall be in addition to the hours required  
14 for the biennial renewal of medical licensure. The Probation shall terminate upon  
15 successful completion of the CME.

16 b. **Obey All Laws**

17 Respondent shall obey all state, federal and local laws, all rules governing the  
18 practice of medicine in Arizona, and remain in full compliance with any court ordered  
19 criminal probation, payments and other orders.

20 c. **Tolling**

21 In the event Respondent should leave Arizona to reside or practice outside the  
22 State or for any reason should Respondent stop practicing medicine in Arizona,  
23 Respondent shall notify the Executive Director in writing within ten days of departure and  
24 return or the dates of non-practice within Arizona. Non-practice is defined as any period of  
25 time exceeding thirty days during which Respondent is not engaging in the practice of

1 medicine. Periods of temporary or permanent residence or practice outside of Arizona or  
2 of non-practice within Arizona, will not apply to the reduction of the probationary period.

3 3. The Board retains jurisdiction and may initiate new action based upon any  
4 violation of this Order. A.R.S. § 32-1401(27)(r).

5 **RIGHT TO PETITION FOR REHEARING OR REVIEW**

6 Respondent is hereby notified that she has the right to petition for a rehearing or  
7 review. The petition for rehearing or review must be filed with the Board's Executive  
8 Director within thirty (30) days after service of this Order. A.R.S. § 41-1092.09(B). The  
9 petition for rehearing or review must set forth legally sufficient reasons for granting a  
10 rehearing or review. A.A.C. R4-16-103. Service of this order is effective five (5) days after  
11 date of mailing. A.R.S. § 41-1092.09(C). If a petition for rehearing or review is not filed,  
12 the Board's Order becomes effective thirty-five (35) days after it is mailed to Respondent.

13 Respondent is further notified that the filing of a motion for rehearing or review is  
14 required to preserve any rights of appeal to the Superior Court.

15 DATED AND EFFECTIVE this 8<sup>th</sup> day of October, 2015.

16 ARIZONA MEDICAL BOARD

17  
18 By Patricia E. McSorley  
19 Patricia E. McSorley  
20 Executive Director

21 EXECUTED COPY of the foregoing mailed  
22 this 8<sup>th</sup> day of October, 2015 to:

23 Dee Dee Holden, Esq.  
24 Holden & Armer, P.C.  
25 6101 South Rural Road, Suite 112  
Tempe, Arizona 85283  
Attorney for Respondent

1 ORIGINAL of the foregoing filed  
2 this 5<sup>th</sup> day of October, 2015 with:

3 Arizona Medical Board  
4 9545 E. Doubletree Ranch Road  
5 Scottsdale, AZ 85258

6 Mary Boyle  
7 Board Staff